Companies › KROS

KEROS THERAPEUTICS INC (KROS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001664710 · EDGAR filings · Updated 2026-07-22

KEROS THERAPEUTICS INC (KROS) has reported institutional ownership of 94.3%, with 150 institutional managers holding positions valued at $205.6M per the latest 13F reporting period.

Filings this week (1)

• 2026-07-22 — Current report (8-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-17 — Insider transaction reported (Form 4)
• 2026-07-17 — SCHEDULE 13G filed
• 2026-07-06 — Insider transaction reported (Form 4)
• 2026-07-06 — Initial insider ownership filed (Form 3)
• 2026-06-25 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KEROS THERAPEUTICS INC has 150 institutional holders and institutional ownership of 94.3%.

Insider activity

Insiders reported 37 transactions (6 buys, 11 sells) across 17 reporting insiders, with a net reported value of −$171.5M.

Related companies

CANDEL THERAPEUTICS INC (CADL) · FOGHORN THERAPEUTICS INC (FHTX) · NAUTILUS BIOTECHNOLOGY INC (NAUT) · OPUS GENETICS INC (IRD) · OCUGEN INC COM (OCGN) · ATRIUM THERAPEUTICS INC (RNA)